89bio to Participate in the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company, announced participation in the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. EST on March 9, with an archived webcast accessible on 89bio’s website. The company focuses on innovative therapies for liver and cardio-metabolic diseases, notably their lead candidate BIO89-100, targeting nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is based in San Francisco.

SAN FRANCISCO, March 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the virtual H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021. An archived webcast will also be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

FAQ

What event will 89bio participate in on March 9-10, 2021?

89bio will participate in the virtual H.C. Wainwright Global Life Sciences Conference.

What time will 89bio's presentation be available during the conference?

The presentation will be available on-demand starting at 7 a.m. EST on March 9, 2021.

Where can I find the archived webcast of 89bio's presentation?

The archived webcast will be accessible in the investor section of 89bio’s website.

What is 89bio's lead product candidate?

89bio's lead product candidate is BIO89-100, developed for treating NASH and SHTG.

What diseases does 89bio focus on?

89bio focuses on the development of therapies for liver and cardio-metabolic diseases.